XERS
Xeris Biopharma·NASDAQ
--
--(--)
--
--(--)
XERS fundamentals
Xeris Biopharma (XERS) expects to report earnings on Mar 2, 2026, with estimated revenue of 82.20M (YoY +44.21%), and EPS at 0.0206 (YoY +168.67%).
Revenue estimate / YoY
82.20M
+44.21%
EPS estimate / YoY
0.0206
+168.67%
Report date
Mar 2, 2026
EPS
Revenue
Revenue & Expenses
XERS has released its 2025 Q3 earnings report, with revenue of 74.38M, reflecting a YoY change of 37.06%, and net profit of 621.00K, showing a YoY change of 103.95%. The Sankey diagram below clearly presents XERS's revenue sources and cost distribution.
Key Indicators
Xeris Biopharma (XERS) key financial stats and ratios, covering profitability, financial health, and leverage.
Xeris Biopharma (XERS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Xeris Biopharma (XERS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Xeris Biopharma (XERS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Xeris Biopharma (XERS) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Xeris Biopharma (XERS) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
What does Xeris Biopharma do and what are its main business segments?What were the key takeaways from Xeris Biopharma's earnings call?Did Xeris Biopharma beat or miss consensus estimates last quarter?What is the market's earnings forecast for Xeris Biopharma next quarter?What factors drove the changes in Xeris Biopharma's revenue and profit?What is the revenue and EPS growth rate for Xeris Biopharma year over year?What is Xeris Biopharma's latest dividend and current dividend yield?What were the key takeaways from Xeris Biopharma’s earnings call?
